by admin | Dec 2, 2019 | Clinical Trials
BAN2401 is a humanized monoclonal antibody that is the result of a strategic research alliance between BioArctic and Eisai. BAN2401 has a unique binding profile and selectively binds to and eliminates soluble, toxic amyloid-beta aggregates (protofibrils) that are...
by admin | Dec 2, 2019 | M&A - Buy-Out
Elsevier, a global information analytics business specializing in science and health, and part of RELX, has acquired 3D4Medical, the global anatomy education company headquartered in Dublin, Ireland. 3D4Medical created Complete Anatomy, the world’s most advanced...
by admin | Dec 2, 2019 | Clinical Trials
TauRx has reportedunexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine on the brain in over 1,000 patients with mild-to-moderate Alzheimer’s...
by admin | Dec 2, 2019 | Partnerships
Sekisui Diagnostics’ Enzyme business unveiled its new Bioprocess Innovation Centre at its site near Maidstone, Kent, UK. The new R&D facility, costing $1.9 million, is part of a long-term investment strategy to grow its share of the Microbial Biopharma CDMO...
by admin | Dec 2, 2019 | FDA
Y-mAbs Therapeutics, a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced that it has submitted to the U.S. Food and Drug Administration...
